Antidepressants and Bone Mineral Density

• Status: Completed
• Trial end date: 2014-04-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this five arm randomized trial was thus to compare selective serotonin reuptake inhibitor (SSRI)sertraline and citalopram to a dual reuptake inhibitor venlafaxine, a nor-adrenaline reuptake inhibitor reboxetine and a control group receiving placebo, with the primary endpoint being bone mineral density, and secondary endpoints being bone turnover markers.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guiyang Medical University
• Treatments: Antidepressive Agents; Citalopram; Dexetimide; Reboxetine; Sertraline; Venlafaxine Hydrochloride

Criteria

Inclusion Criteria:

• Participants needed to have a primary diagnosis of depression with Zung Self Rated Depression Scale (SDS) > 53, and Hamilton Depression Scale (HAMD) ≥20.

Exclusion Criteria:

• The patients with hyperparathyroidism, myeloma or other disorders known to affect bone metabolism

• Use of estrogen

• Calcitonin drugs

• Previous antidepressant or other psychiatric drug use or prior treatment history